MedTrace Logo

Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung Cancer (NSCLC)

NCT00763607 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 454

Last updated 2022-09-10

No results posted yet for this study

Summary

Aim of the study is to evaluated the role of IGF1R and p95HER2 on prognosis in radically resected non small cell lung cancer patients

The primary objective is to correlate the expression of IGF1R and p95HER2 with survival.

Conditions

  • Non Small Cell Lung Cancer

Interventions

GENETIC

Protein expression by immunohistochemistry and immunofluorescence

Protein expression by immunohistochemistry and immunofluorescence

Sponsors & Collaborators

  • Armando Santoro, MD

    lead OTHER

Principal Investigators

  • Armando Santoro, MD · Istituto Clinico Humanitas

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00763607 on ClinicalTrials.gov